NCT03733925View on ClinicalTrials.gov

A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 7, 2019

Primary Completion Date

November 15, 2021

Study Completion Date

November 15, 2021

Conditions
Spondylitis, AnkylosingArthritis, Psoriatic
Interventions
DRUG

Golimumab

Participants will receive golimumab 50 mg SC injections at Week 0 and q4w thereafter through Week 24.

Trial Locations (9)

110029

All India Institute of Medical Sciences, New Delhi

110060

Sir Ganga Ram Hospital, New Delhi

411005

Sancheti Institute for Orthopedics & Rehabilitation, Pune

500082

Nizams Institute of Medical Sciences NIMS, Hyderabad

560079

ChanRe Rheumatology And Immunology Center And Research, Bangalore

600004

Chennai Meenakshi Multispeciality Hospital, Chennai

700019

Apollo Multispeciality Hospital Ltd, Kolkata

751005

Apollo Hospitals, Bhubaneswar

1100776

Indraprastha Apollo Hospital, New Delhi

Sponsors
All Listed Sponsors
lead

Johnson & Johnson Private Limited

INDUSTRY